CMS and FDA launch RAPID pathway for breakthrough device coverage

Overview

For nearly a decade, medical device makers have faced the same bottleneck: the FDA clears a breakthrough device, and then Medicare spends another year or more deciding whether to pay for it. On April 23, 2026, the two agencies jointly announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway to collapse that gap to as little as two months — and simultaneously paused the existing Transitional Coverage for Emerging Technologies (TCET) program for new applicants, consolidating all breakthrough-device coverage work under the new pathway.

RAPID synchronizes FDA premarket review with Medicare's national coverage decision. Manufacturers agree upfront on what evidence the Centers for Medicare and Medicaid Services (CMS) needs; CMS issues a proposed coverage decision the same day the FDA clears the device; a 30-day public comment window follows. About 40 devices in the FDA's Breakthrough Devices Program qualify today, with roughly 20 more potentially eligible — concentrated in cardiology, neurology, and chronic-care technology. Industry group AdvaMed called the pathway a positive step but warned that without meaningful timelines and accountability built into program management, patients may not see the full benefits.

Why it matters

Medicare beneficiaries with serious heart, neurological, and chronic conditions could access newly approved devices nearly a year earlier than before.

Play on this story Voices Debate Who Said What? Predict

Key Indicators

~2 months

New time to Medicare coverage

Target interval between FDA market authorization and final national coverage decision under RAPID.

1 year+

Current time to coverage

Typical delay between FDA clearance and a Medicare national coverage decision under existing process.

~40

Devices eligible now

Breakthrough devices that could qualify for the RAPID pathway immediately, per a senior CMS official.

~20

Additional potential qualifiers

Further devices that could meet RAPID criteria as evidence plans develop.

60 days

Public comment period

Federal Register comment window on the proposed procedural notice before CMS finalizes the pathway.

~250

Cardiology breakthrough devices

Cardiology has the largest share of devices in the FDA Breakthrough Devices Program and stands to benefit most.

Interactive

Exploring all sides of a story is often best achieved with Play.

Ayn Rand

(1905-1982) · Cold War · philosophy

Fictional AI pastiche — not real quote.

"At last, the bureaucratic hydra consents to trim one of its own heads — not out of principle, but because the absurdity of rewarding innovation with a year of administrative purgatory had become too embarrassing even for Washington. I will celebrate this rationality when it is permanent, and not merely a temporary mercy extended to the productive by those who have never created a thing themselves."

Ever wondered what historical figures would say about today's headlines?

People Involved

Marty Makary

Co-announcing RAPID pathway

Dr. Mehmet Oz

Co-announcing RAPID pathway

Organizations Involved

Centers for Medicare & Medicaid Services

Federal Agency

Issuing proposed procedural notice; TCET pathway paused for new candidates

The federal agency that decides what Medicare pays for and at what rate.

U.S. Food and Drug Administration

Federal regulatory agency

Co-issuing RAPID pathway

The federal agency that reviews medical devices for safety and effectiveness before market authorization.

AdvaMed

Industry Trade Association

Supporting pathway, lobbying for broader coverage

The largest U.S. trade association representing medical device manufacturers.

Timeline

RAPID coverage pathway announced
Regulation

CMS and FDA jointly announce the Regulatory Alignment for Predictable and Immediate Device pathway, targeting Medicare coverage as fast as two months after FDA clearance.
April 23rd, 2026
CMS pauses TCET pathway for new candidates
Regulation

Alongside the RAPID launch, CMS announced it is pausing the Transitional Coverage for Emerging Technologies program for new applicants, directing breakthrough-device coverage resources entirely toward RAPID implementation.
April 23rd, 2026
CMS proposes payment rollback for breakthrough devices
Regulation

CMS proposes eliminating the alternate new technology add-on payment pathway that lets breakthrough devices skip the substantial-clinical-improvement test.
April 15th, 2026
TCET pathway finalized
Regulation

CMS finalizes TCET, targeting a six-month national coverage decision after FDA authorization, capped at roughly five devices per year.
August 12th, 2024
TCET pathway proposed
Regulation

CMS publishes proposed Transitional Coverage for Emerging Technologies pathway, a narrower successor to MCIT.
June 28th, 2023
Biden CMS rescinds MCIT
Regulation

CMS repeals the MCIT rule, citing insufficient patient safeguards and weak incentives for post-market evidence development.
November 15th, 2021
MCIT rule finalized
Regulation

Outgoing Trump administration finalizes Medicare Coverage of Innovative Technology rule granting four years of automatic Medicare coverage to FDA breakthrough devices.
January 14th, 2021
21st Century Cures Act signed into law
Legislation

Creates the FDA Breakthrough Devices designation, giving priority review to devices that treat serious conditions with unmet medical need.
December 13th, 2016

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Predictions leaderboard

RAPID finalized as proposed, first devices covered by late 2026

The 60-day comment period closes with support from industry and muted pushback from payer-evidence groups. CMS finalizes the procedural notice in the third quarter, and the first two to three breakthrough devices — likely cardiology implants — secure national coverage within two months of FDA clearance by year-end. Manufacturers move trial designs to pre-align evidence with CMS.

Discussed by: AdvaMed, STAT, MedTech Dive analysts

Consensus —

Faster coverage, smaller payments: RAPID paired with add-on rollback squeezes economics

RAPID advances alongside CMS's April 15 proposal to strip breakthrough devices of preferential new technology add-on payments. Devices gain coverage faster but at standard reimbursement rates, narrowing the commercial upside manufacturers expected. Smaller firms with thin margins delay launches or deprioritize Medicare populations in trial design.

Discussed by: Modern Healthcare, Healthcare Dive, device-industry analysts

Consensus —

Comment period surfaces evidence concerns, CMS adds safeguards

Patient advocacy and health services researchers echo the 2021 critique that triggered MCIT's repeal: real-world performance in Medicare populations often diverges from pivotal trial data. CMS responds in its final notice by requiring mandatory coverage with evidence development or shorter coverage durations, trimming the two-month timeline in practice.

Discussed by: Health Affairs authors, former CMS coverage officials

Consensus —

Legal challenge to same-day proposed NCD

Critics argue that issuing a proposed national coverage determination on the day of FDA clearance bypasses the deliberative review Medicare statute contemplates. A payer coalition or beneficiary group files suit seeking to block the pathway, forcing CMS to defend its statutory authority and potentially delaying first coverage decisions.

Discussed by: Health law practitioners, Reed Smith health regulatory blog

Consensus —

Historical Context

MCIT rule and rescission (2021)

January–November 2021

What Happened

In its final days, the first Trump administration finalized the Medicare Coverage of Innovative Technology rule, giving FDA breakthrough devices four years of automatic Medicare coverage starting at market authorization. The Biden CMS delayed implementation, then formally repealed the rule in November 2021, arguing the four-year window cut off the agency's ability to demand evidence on how devices performed in older, sicker Medicare patients.

Outcome

Short Term

Device makers lost automatic coverage; the coverage gap reverted to roughly a year or longer. AdvaMed launched a multi-year lobbying push for a replacement.

Long Term

The rescission established that tying Medicare coverage directly to FDA approval raised unresolved evidence-standard questions, forcing successor programs to build in pre-market evidence negotiation rather than post-market automatic coverage.

Why It's Relevant Today

RAPID is the third attempt to bridge the FDA-to-Medicare gap. It borrows MCIT's speed ambition but answers the 2021 critique by requiring Medicare-specific trial enrollment and agreed outcomes before approval — not coverage first, evidence later.

TCET pathway finalized (2024)

August 2024

What Happened

The Biden CMS finalized the Transitional Coverage for Emerging Technologies pathway, targeting a six-month national coverage decision after FDA breakthrough device authorization. The program accepted up to five devices per year, required coverage with evidence development, and was intended as a modest, defensible successor to MCIT.

Outcome

Short Term

Industry groups welcomed TCET as better than nothing but criticized the five-device cap as far too narrow given the pipeline.

Long Term

TCET set the procedural template — concurrent review, upfront evidence planning — that RAPID scales up. RAPID removes the five-device cap, cuts the timeline further, and broadens eligibility to include Class II devices in FDA's TAP program.

Why It's Relevant Today

RAPID is essentially TCET with the throttle removed. Whether the faster timeline survives public comment intact will hinge on whether the evidence safeguards carried over from TCET persuade skeptics.

FDA Breakthrough Therapy designation for drugs (2012)

July 2012

What Happened

Congress created the Breakthrough Therapy designation under FDASIA, letting FDA work closely with drug sponsors from early development to speed approval of therapies for serious conditions. Unlike devices, drugs face a separate Medicare coverage mechanism (Part B/D) that does not require national coverage determinations for most products, so approval and reimbursement historically ran in closer sequence.

Outcome

Short Term

Dozens of cancer, rare disease, and infectious disease drugs reached patients one to two years earlier than traditional review would have allowed.

Long Term

The designation normalized the idea that regulators can engineer closer collaboration with sponsors on evidence design without abandoning safety and efficacy standards — the template RAPID now extends to devices plus payers.

Why It's Relevant Today

Drugs have had an accelerated front door for more than a decade; devices never bridged the coverage gap that separates approval from reimbursement. RAPID is the structural import of that drug-side playbook into the device and Medicare coverage world.